Aim immunotech announces positive progress on requested fda meeting for proposed ampligen clinical trial in post-covid-19 cognitive dysfunction

Ocala, fla., sept. 21, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced positive progress with the company's meeting request to the u.s. food and drug administration (fda) concerning a phase 2 clinical study of ampligen as an infusion therapy for post-covid-19 cognitive dysfunction (pccd). the meeting request has been deemed sufficient for transfer to the fda's division of neurology by the fda's covid scientific technical triage team.
AIM Ratings Summary
AIM Quant Ranking